STAT5a and STAT6 gene expression levels in multiple sclerosis patients.

Area of Science:

• Neuroimmunology
• Molecular Biology

Background:

• Multiple sclerosis (MS) is an autoimmune CNS disease characterized by inflammation.
• Cytokines and the Janus kinase/signal transducers and activators of transcriptions (JAK/STAT) pathway are implicated in MS pathogenesis.
• Dysregulation of the JAK/STAT pathway is linked to adverse pathological outcomes in MS.

Purpose of the Study:

• To compare the expression levels of STAT5a and STAT6 genes in relapsing-remitting MS (RR-MS) patients and healthy controls.
• To investigate the correlation between STAT5a and STAT6 gene expression and clinical parameters in MS patients.

Main Methods:

• Blood samples were collected from 50 RR-MS patients and 50 healthy controls.
• Taqman Quantitative Real-Time PCR was used to measure STAT5a and STAT6 gene expression.
• Correlation analysis was performed between gene expression and the Kurtzke Expanded Disability Status Scale (EDSS).

Main Results:

• STAT5a gene expression was significantly down-regulated in MS patients compared to controls (p = .049).
• STAT6 gene expression was significantly up-regulated in MS patients compared to controls (p = .046).
• STAT6 expression correlated significantly with EDSS scores, while STAT5a expression did not correlate with clinical findings or STAT6 expression.

Conclusions:

• STAT5a and STAT6 gene dysregulation may contribute to immune response imbalance in MS.
• Further research is needed to elucidate the precise mechanisms and potential of STAT5a and STAT6 as biomarkers for MS.